Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 3/2015

01.05.2015 | Glycogenoses

Dietary management in glycogen storage disease type III: what is the evidence?

verfasst von: Terry G. J. Derks, G. Peter A. Smit

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

In childhood, GSD type III causes relatively severe fasting intolerance, classically associated with ketotic hypoglycaemia. During follow up, history of (documented) hypoglycaemia, clinical parameters (growth, liver size, motor development, neuromuscular parameters), laboratory parameters (glucose, lactate, ALAT, cholesterol, triglycerides, creatine kinase and ketones) and cardiac parameters all need to be integrated in order to titrate dietary management, for which age-dependent requirements need to be taken into account. Evidence from case studies and small cohort studies in both children and adults with GSD III demonstrate that prevention of hypoglycaemia and maintenance of euglycemia is not sufficient to prevent complications. Moreover, over-treatment with carbohydrates may even be harmful. The ageing cohort of GSD III patients, including the non-traditional clinical presentations in adulthood, raises ‬‬‬new questions.
Literatur
Zurück zum Zitat Bhattacharya K, Orton RC, Qi X et al (2007) A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis 30:350–357CrossRefPubMed Bhattacharya K, Orton RC, Qi X et al (2007) A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis 30:350–357CrossRefPubMed
Zurück zum Zitat Bhatti S, Parry E (2006) Successful pregnancy in a woman with glycogen storage disease type III. Aust N Z J Obstet Gynaecol 46:168–169CrossRefPubMed Bhatti S, Parry E (2006) Successful pregnancy in a woman with glycogen storage disease type III. Aust N Z J Obstet Gynaecol 46:168–169CrossRefPubMed
Zurück zum Zitat Bier DM, Leake RD, Haymond MW, Arnold KJ, Gruenke LD, Sperling MA, Kipnis DM (1977) Measurement of “true” glucose production rates in infancy and childhood with 6,6-dideuteroglucose. Diabetes 26:1016–1023CrossRefPubMed Bier DM, Leake RD, Haymond MW, Arnold KJ, Gruenke LD, Sperling MA, Kipnis DM (1977) Measurement of “true” glucose production rates in infancy and childhood with 6,6-dideuteroglucose. Diabetes 26:1016–1023CrossRefPubMed
Zurück zum Zitat Bolton SD, Clark VA, Norman JE (2012) Multidisciplinary management of an obstetric patient with glycogen storage disease type 3. Int J Obstet Anesth 21:86–89CrossRefPubMed Bolton SD, Clark VA, Norman JE (2012) Multidisciplinary management of an obstetric patient with glycogen storage disease type 3. Int J Obstet Anesth 21:86–89CrossRefPubMed
Zurück zum Zitat Bonnefont JP, Specola NB, Vassault A et al (1990) The fasting test in paediatrics: application to the diagnosis of pathological hypo- and hyperketotic states. Eur J Pediatr 150:80–85CrossRefPubMed Bonnefont JP, Specola NB, Vassault A et al (1990) The fasting test in paediatrics: application to the diagnosis of pathological hypo- and hyperketotic states. Eur J Pediatr 150:80–85CrossRefPubMed
Zurück zum Zitat Chen YT, Cornblath M, Sidbury JB (1984) Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 310:171–175CrossRefPubMed Chen YT, Cornblath M, Sidbury JB (1984) Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 310:171–175CrossRefPubMed
Zurück zum Zitat Confino E, Pauzner D, Lidor A, Yedwab G, David M (1984) Pregnancy associated with amylo-1,6-glucosidase deficiency (Forbe’s disease). Case report. Br J Obstet Gynaecol 91:494–497CrossRefPubMed Confino E, Pauzner D, Lidor A, Yedwab G, David M (1984) Pregnancy associated with amylo-1,6-glucosidase deficiency (Forbe’s disease). Case report. Br J Obstet Gynaecol 91:494–497CrossRefPubMed
Zurück zum Zitat Correia CE, Bhattacharya K, Lee PJ et al (2008) Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr 88:1272–1276PubMedCentralPubMed Correia CE, Bhattacharya K, Lee PJ et al (2008) Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr 88:1272–1276PubMedCentralPubMed
Zurück zum Zitat Dagli AI, Zori RT, McCune H, Ivsic T, Maisenbacher MK, Weinstein DA (2009) Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. J Inherit Metab Dis 32(Suppl 1):S103–S106CrossRefPubMed Dagli AI, Zori RT, McCune H, Ivsic T, Maisenbacher MK, Weinstein DA (2009) Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. J Inherit Metab Dis 32(Suppl 1):S103–S106CrossRefPubMed
Zurück zum Zitat Dagli A, Sentner CP, Weinstein DA (2010) Glycogen storage disease type III. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews(R). University of Washington, Seattle, Seattle Dagli A, Sentner CP, Weinstein DA (2010) Glycogen storage disease type III. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews(R). University of Washington, Seattle, Seattle
Zurück zum Zitat Fernandes J, van de Kamer JH (1968) Hexose and protein tolerance tests in children with liver glycogenosis caused by a deficiency of the debranching enzyme system. Pediatrics 41:935–944PubMed Fernandes J, van de Kamer JH (1968) Hexose and protein tolerance tests in children with liver glycogenosis caused by a deficiency of the debranching enzyme system. Pediatrics 41:935–944PubMed
Zurück zum Zitat Fernandes J, Koster JF, Grose WF, Sorgedrager N (1974) Hepatic phosphorylase deficiency. Its differentiation from other hepatic glycogenoses. Arch Dis Child 49:186–191CrossRefPubMedCentralPubMed Fernandes J, Koster JF, Grose WF, Sorgedrager N (1974) Hepatic phosphorylase deficiency. Its differentiation from other hepatic glycogenoses. Arch Dis Child 49:186–191CrossRefPubMedCentralPubMed
Zurück zum Zitat Hayde M, Widhalm K (1990) Effects of cornstarch treatment in very young children with type I glycogen storage disease. Eur J Pediatr 149:630–633CrossRefPubMed Hayde M, Widhalm K (1990) Effects of cornstarch treatment in very young children with type I glycogen storage disease. Eur J Pediatr 149:630–633CrossRefPubMed
Zurück zum Zitat Kalhan SC, D'Angelo LJ, Savin SM, Adam PA (1979) Glucose production in pregnant women at term gestation. Sources of glucose for human fetus. J Clin Invest 63:388–394CrossRefPubMedCentralPubMed Kalhan SC, D'Angelo LJ, Savin SM, Adam PA (1979) Glucose production in pregnant women at term gestation. Sources of glucose for human fetus. J Clin Invest 63:388–394CrossRefPubMedCentralPubMed
Zurück zum Zitat Kiechl S, Willeit J, Vogel W, Kohlendorfer U, Poewe W (1999) Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis. Neuromuscul Disord 9:408–410CrossRefPubMed Kiechl S, Willeit J, Vogel W, Kohlendorfer U, Poewe W (1999) Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis. Neuromuscul Disord 9:408–410CrossRefPubMed
Zurück zum Zitat Kishnani PS, Austin SL, Arn P et al (2010) Glycogen storage disease type III diagnosis and management guidelines. Genet Med 12:446–463CrossRefPubMed Kishnani PS, Austin SL, Arn P et al (2010) Glycogen storage disease type III diagnosis and management guidelines. Genet Med 12:446–463CrossRefPubMed
Zurück zum Zitat Labrune P, Huguet P, Odievre M (1991) Cardiomyopathy in glycogen-storage disease type III: clinical and echographic study of 18 patients. Pediatr Cardiol 12:161–163CrossRefPubMed Labrune P, Huguet P, Odievre M (1991) Cardiomyopathy in glycogen-storage disease type III: clinical and echographic study of 18 patients. Pediatr Cardiol 12:161–163CrossRefPubMed
Zurück zum Zitat Laforêt P, Weinstein DA, Smit GPA (2011) Chapter 6: the glycogen storage diseases and related disorders. In: Saudubray JM, van den Berghe G, Walter J (eds) Inborn metabolic diseases Laforêt P, Weinstein DA, Smit GPA (2011) Chapter 6: the glycogen storage diseases and related disorders. In: Saudubray JM, van den Berghe G, Walter J (eds) Inborn metabolic diseases
Zurück zum Zitat Lee P (1999) Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gynaecol 106:181–182PubMed Lee P (1999) Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gynaecol 106:181–182PubMed
Zurück zum Zitat Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV (1997) Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. Am J Cardiol 79:834–838CrossRefPubMed Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV (1997) Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. Am J Cardiol 79:834–838CrossRefPubMed
Zurück zum Zitat Mendoza A, Fisher NC, Duckett J et al (1998) Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gynaecol 105:677–680CrossRefPubMed Mendoza A, Fisher NC, Duckett J et al (1998) Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gynaecol 105:677–680CrossRefPubMed
Zurück zum Zitat Moe PJ, Waaler PE, Garatun-Tjeldsto O (1972) Glycogen storage disease type 3 and diabetes mellitus. Acta Paediatr Scand 61:483–486CrossRefPubMed Moe PJ, Waaler PE, Garatun-Tjeldsto O (1972) Glycogen storage disease type 3 and diabetes mellitus. Acta Paediatr Scand 61:483–486CrossRefPubMed
Zurück zum Zitat Nalin T, Venema K, Weinstein DA et al (2014) In vitro digestion of starches in a dynamic gastrointestinal model: an innovative study to optimize dietary management of patients with hepatic glycogen storage diseases. J Inherit Metab Dis. doi:10.1007/s10545-014-9763-y Nalin T, Venema K, Weinstein DA et al (2014) In vitro digestion of starches in a dynamic gastrointestinal model: an innovative study to optimize dietary management of patients with hepatic glycogen storage diseases. J Inherit Metab Dis. doi:10.​1007/​s10545-014-9763-y
Zurück zum Zitat Oki Y, Okubo M, Tanaka S, Nakanishi K, Kobayashi T, Murase T (2000) Diabetes mellitus secondary to glycogen storage disease type III. Diabet Med 17:810–812CrossRefPubMed Oki Y, Okubo M, Tanaka S, Nakanishi K, Kobayashi T, Murase T (2000) Diabetes mellitus secondary to glycogen storage disease type III. Diabet Med 17:810–812CrossRefPubMed
Zurück zum Zitat Okubo M, Horinishi A, Nakamura N, Aoyama Y, Hashimoto M, Endo Y, Murase T (1998) A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12–>G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb. Hum Genet 102:1–5CrossRefPubMed Okubo M, Horinishi A, Nakamura N, Aoyama Y, Hashimoto M, Endo Y, Murase T (1998) A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12–>G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb. Hum Genet 102:1–5CrossRefPubMed
Zurück zum Zitat Preisler N, Pradel A, Husu E et al (2013) Exercise intolerance in glycogen storage disease type III: weakness or energy deficiency? Mol Genet Metab 109:14–20CrossRefPubMed Preisler N, Pradel A, Husu E et al (2013) Exercise intolerance in glycogen storage disease type III: weakness or energy deficiency? Mol Genet Metab 109:14–20CrossRefPubMed
Zurück zum Zitat Ramachandran R, Wedatilake Y, Coats C et al (2012) Pregnancy and its management in women with GSD type III—a single centre experience. J Inherit Metab Dis 35:245–251CrossRefPubMed Ramachandran R, Wedatilake Y, Coats C et al (2012) Pregnancy and its management in women with GSD type III—a single centre experience. J Inherit Metab Dis 35:245–251CrossRefPubMed
Zurück zum Zitat Ravaglia S, Pichiecchio A, Rossi M et al (2006) Dietary treatment in adult-onset type II glycogenosis. J Inherit Metab Dis 29:590CrossRefPubMed Ravaglia S, Pichiecchio A, Rossi M et al (2006) Dietary treatment in adult-onset type II glycogenosis. J Inherit Metab Dis 29:590CrossRefPubMed
Zurück zum Zitat Ruderman NB (1975) Muscle amino acid metabolism and gluconeogenesis. Annu Rev Med 26:245–258CrossRefPubMed Ruderman NB (1975) Muscle amino acid metabolism and gluconeogenesis. Annu Rev Med 26:245–258CrossRefPubMed
Zurück zum Zitat Sentner CP, Caliskan K, Vletter WB, Smit GP (2012) Heart failure due to severe hypertrophic cardiomyopathy reversed by low calorie, high protein dietary adjustments in a glycogen storage disease type iiia patient. JIMD Rep 5:13–16CrossRefPubMedCentralPubMed Sentner CP, Caliskan K, Vletter WB, Smit GP (2012) Heart failure due to severe hypertrophic cardiomyopathy reversed by low calorie, high protein dietary adjustments in a glycogen storage disease type iiia patient. JIMD Rep 5:13–16CrossRefPubMedCentralPubMed
Zurück zum Zitat Sharma RWS (2009) Diabetes in patients with glycogen storage disease types I and III. Diabet Med J Br Diabet Assoc 26:102 Sharma RWS (2009) Diabetes in patients with glycogen storage disease types I and III. Diabet Med J Br Diabet Assoc 26:102
Zurück zum Zitat Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT (1996) Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 98:352–357CrossRefPubMedCentralPubMed Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT (1996) Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 98:352–357CrossRefPubMedCentralPubMed
Zurück zum Zitat Slonim AE, Weisberg C, Benke P, Evans OB, Burr IM (1982) Reversal of debrancher deficiency myopathy by the use of high-protein nutrition. Ann Neurol 11:420–422CrossRefPubMed Slonim AE, Weisberg C, Benke P, Evans OB, Burr IM (1982) Reversal of debrancher deficiency myopathy by the use of high-protein nutrition. Ann Neurol 11:420–422CrossRefPubMed
Zurück zum Zitat Slonim AE, Coleman RA, Moses WS (1984) Myopathy and growth failure in debrancher enzyme deficiency: improvement with high-protein nocturnal enteral therapy. J Pediatr 105:906–911CrossRefPubMed Slonim AE, Coleman RA, Moses WS (1984) Myopathy and growth failure in debrancher enzyme deficiency: improvement with high-protein nocturnal enteral therapy. J Pediatr 105:906–911CrossRefPubMed
Zurück zum Zitat Smit GP, Berger R, Potasnick R, Moses SW, Fernandes J (1984) The dietary treatment of children with type I glycogen storage disease with slow release carbohydrate. Pediatr Res 18:879–881CrossRefPubMed Smit GP, Berger R, Potasnick R, Moses SW, Fernandes J (1984) The dietary treatment of children with type I glycogen storage disease with slow release carbohydrate. Pediatr Res 18:879–881CrossRefPubMed
Zurück zum Zitat Spengos K, Michelakakis H, Vontzalidis A, Zouvelou V, Manta P (2009) Diabetes mellitus associated with glycogen storage disease type III. Muscle Nerve 39:876–877CrossRefPubMed Spengos K, Michelakakis H, Vontzalidis A, Zouvelou V, Manta P (2009) Diabetes mellitus associated with glycogen storage disease type III. Muscle Nerve 39:876–877CrossRefPubMed
Zurück zum Zitat Talente GM, Coleman RA, Alter C et al (1994) Glycogen storage disease in adults. Ann Intern Med 120:218–226CrossRefPubMed Talente GM, Coleman RA, Alter C et al (1994) Glycogen storage disease in adults. Ann Intern Med 120:218–226CrossRefPubMed
Zurück zum Zitat Tsilianidis LA, Fiske LM, Siegel S et al (2013) Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab 109:179–182CrossRefPubMedCentralPubMed Tsilianidis LA, Fiske LM, Siegel S et al (2013) Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab 109:179–182CrossRefPubMedCentralPubMed
Zurück zum Zitat Valayannopoulos V, Bajolle F, Arnoux J et al (2011) Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res 70:638–641CrossRefPubMed Valayannopoulos V, Bajolle F, Arnoux J et al (2011) Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res 70:638–641CrossRefPubMed
Zurück zum Zitat van Veen MR, van Hasselt PM, de Sain-van der Velden MG, Verhoeven N, Hofstede FC, de Koning TJ, Visser G (2011) Metabolic profiles in children during fasting. Pediatrics 127:e1021–e1027CrossRefPubMed van Veen MR, van Hasselt PM, de Sain-van der Velden MG, Verhoeven N, Hofstede FC, de Koning TJ, Visser G (2011) Metabolic profiles in children during fasting. Pediatrics 127:e1021–e1027CrossRefPubMed
Zurück zum Zitat Vertilus SM, Austin SL, Foster KS et al (2010) Echocardiographic manifestations of glycogen storage disease III: increase in wall thickness and left ventricular mass over time. Genet Med 12:413–423CrossRefPubMedCentralPubMed Vertilus SM, Austin SL, Foster KS et al (2010) Echocardiographic manifestations of glycogen storage disease III: increase in wall thickness and left ventricular mass over time. Genet Med 12:413–423CrossRefPubMedCentralPubMed
Zurück zum Zitat Wahren J, Ekberg K, Fernqvist-Forbes E, Nair S (1999) Brain substrate utilisation during acute hypoglycaemia. Diabetologia 42:812–818CrossRefPubMed Wahren J, Ekberg K, Fernqvist-Forbes E, Nair S (1999) Brain substrate utilisation during acute hypoglycaemia. Diabetologia 42:812–818CrossRefPubMed
Zurück zum Zitat Zijlmans WC, van Kempen AA, Serlie MJ, Sauerwein HP (2009) Glucose metabolism in children: influence of age, fasting, and infectious diseases. Metabolism 58:1356–1365CrossRefPubMed Zijlmans WC, van Kempen AA, Serlie MJ, Sauerwein HP (2009) Glucose metabolism in children: influence of age, fasting, and infectious diseases. Metabolism 58:1356–1365CrossRefPubMed
Metadaten
Titel
Dietary management in glycogen storage disease type III: what is the evidence?
verfasst von
Terry G. J. Derks
G. Peter A. Smit
Publikationsdatum
01.05.2015
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 3/2015
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-014-9756-x

Weitere Artikel der Ausgabe 3/2015

Journal of Inherited Metabolic Disease 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.